Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(antihemophilic factor)
28,087 results
  • Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A. [Journal Article]
    N Engl J Med. 2023 Jan 26; 388(4):310-318.von Drygalski A, Chowdary P, … XTEND-1 Trial Group
  • CONCLUSIONS: In patients with severe hemophilia A, once-weekly efanesoctocog alfa provided superior bleeding prevention to prestudy prophylaxis, normal to near-normal factor VIII activity, and improvements in physical health, pain, and joint health. (Funded by Sanofi and Sobi; XTEND-1 ClinicalTrials.gov number, NCT04161495.).
  • [NEW INNOVATIONS IN THE TREATMENT OF HEMOPHILIA]. [Review]
    Harefuah. 2023 Jan; 162(1):47-51.Levy-Mendelovich S, Brutman-Barazani T, Kenet G
  • Hemophilia is a congenital bleeding disorder with a deficiency of coagulation factor 8 or 9 (hemophilia A or B, respectively) and a tendency for recurrent bleeding, especially into muscles and joints, which may cause orthopedic damage and necessitate joint replacement surgeries at a young age. In recent years, there has been a huge breakthrough in the treatment of hemophilia. Until recently, the …
  • Protein S Deficiency with Recurrent Deep Vein Thrombosis and Post Thrombotic Syndrome: A Case Report. [Case Reports]
    JNMA J Nepal Med Assoc. 2022 Oct 01; 60(254):892-894.Neupane S, Pudasaini P, … Subedi B
  • Protein S is a vitamin K-dependent protein that acts as a break in secondary hemostasis by inactivating activated factor V and activated factor VIII. We report a case of a 40 years old male who had the first episode of deep vein thrombosis of the left lower limb 10 years back, which despite treatment, reoccurred 3 months later in the bilateral lower limb. Thrombophilic screening showed severe pro…
  • Therapeutic potential of fetal liver cells transplantation in hemophilia A mice. [Journal Article]
    Haematologica. 2023 Jan 26 [Online ahead of print]Merlin S, Akula S, … Follenzi A
  • Hemophilia A (HA) cell therapy approaches in pediatric individuals require suitable factor (F)VIII-producing cells for stable engraftment. Liver sinusoidal endothelial cells (LSEC) and hematopoietic stem cells (HSC) have been demonstrated to be suitable for the treatment of adult HA-mice. However, after transplantation in busulfan (BU)-conditioned newborn mice, adult LSEC/HSC cannot efficiently e…
  • Acquired Hemophilia A In Adults: A Multicenter Study from Turkey. [Journal Article]
    Indian J Hematol Blood Transfus. 2023 Jan; 39(1):107-115.Arslan Davulcu E, Demirci Z, … Şahin F
  • Acquired hemophilia A (AHA) is a rare disease caused by autoantibodies inhibiting factor VIII (FVIII) activity. Although the conditionis usually idiopathic, there may be other underlying diseases. Treatment consists of two steps: treatment of acute bleeding and immunosuppression. In this multicenter study, we aimed to demonstrate the clinical characteristics, management details, and survival of A…
  • Gene therapy for hemophilia: looking beyond factor expression. [Review]
    Exp Biol Med (Maywood). 2023 Jan 23 [Online ahead of print]Yamaguti-Hayakawa GG, Ozelo MC
  • Hemophilia A (factor VIII [FVIII] deficiency) and hemophilia B (factor IX [FIX] deficiency) are the X-linked recessive bleeding disorders that clinically manifest with recurrent bleeding, predominantly into muscles and joints. In its severe presentation, when factor activity is less than 1% of normal, hemophilia presents with spontaneous musculoskeletal bleeds and may progress to debilitating chr…
  • Factor assay in victims of snake bite: Experience from a tertiary care institute in South India. [Journal Article]
    Asian J Transfus Sci. 2022 Jul-Dec; 16(2):175-179.Rafi AM, Innah SJ
  • CONCLUSIONS: Early detection and treatment of envenomation remains the cornerstone of managing snake venom-induced consumptive coagulopathy. Anti-snake venom plays a major role in the reversal of coagulopathy. Blood and blood products would be useful when coagulopathy does not revert by ASV alone. Evidence-based transfusion can be implemented and cryoprecipitate may be used as many of the patients had factor XIII and fibrinogen deficiency as part of venom-induced coagulopathy. To improve patient management and thereby the outcome of patients CMEs and training programs for the treating physicians also has to be implemented so that guidelines are formulated and followed.
  • Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands. [Review]
    Pharmaceutics. 2022 Dec 26; 15(1)Zlotos DP, Kronenberger T, Laufer SA
  • Hormone-dependent cancers, such as certain types of breast cancer are characterized by over-expression of estrogen receptors (ERs). Anticancer drug conjugates combining ER ligands with other classes of anticancer agents may not only benefit from dual action at both anti-cancer targets but also from selective delivery of cytotoxic agents to ER-positive tumor cells resulting in less toxicity and ad…
  • Desmopressin as a hemostatic and blood sparing agent in bleeding disorders. [Review]
    Eur J Haematol. 2023 Jan 19 [Online ahead of print]Mohinani A, Patel S, … Shatzel J
  • Intranasal, subcutaneous, or intravenous desmopressin can be utilized to release von Willebrand Factor and Factor VIII into circulation, enhance platelet adhesion and shorten bleeding time. Due to these properties, desmopressin can be effective in controlling bleeding in mild hemophilia A, certain subtypes of von Willebrand disease and in acute bleeding from uremia, end stage renal disease, and l…
New Search Next